Efficacy and safety of belimumab versus rituximab for refractory immune thrombocytopenia in patients with connective tissue disease
BLM may be a safe and effective alternative to RTX for CTD-ITP refractory to GCs plus ISAs.
Authors
- Ying Jiang (ORCID: https://orcid.org/0000-0001-6269-0172)
- Xiangning Yuan (ORCID: https://orcid.org/0000-0002-6472-3721)
- Yudong Liu (ORCID: https://orcid.org/0000-0002-5153-3400)
- Min Wang (ORCID: https://orcid.org/0000-0002-2357-589X)
- Xuan Zhang (ORCID: https://orcid.org/0000-0001-8775-1699)
- Xiaoxia Zuo
- Tong Li (ORCID: https://orcid.org/0000-0003-3725-1420)
Institutions
- Central South University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Beijing Geriatric Hospital (CN)
- Beijing Hospital (CN)
- Xiangya Hospital Central South University (CN)
Publication Details
- Journal
- Lupus Science & Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/lupus-2025-001501
- Citations
- 3
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 5.31
Funders
- National Natural Science Foundation of China
- University of South China
- Xiangya Hospital, Central South University
- National Key Research and Development Program of China